SCHEMBL14909151

SCHEMBL14909151

Brc1cc(N2CCOCC2)nc2[nH]ccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 6/20 0.55
PIK3R1 P27986 1/20 0.55
JAK3 P52333 3/20 0.49
MTOR P42345 5/20 0.46
ATR Q13535 4/20 0.43
ATRIP Q8WXE1 1/20 0.43
TTBK1 Q5TCY1 2/20 0.42
TTBK2 Q6IQ55 2/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CHEK1 O14757 2/20 0.42
AURKA O14965 2/20 0.42
JAK2 O60674 2/20 0.42
MAP4K4 O95819 2/20 0.42
PAK4 O96013 2/20 0.42
ABL1 P00519 2/20 0.42
CSF1R P07333 2/20 0.42
RET P07949 2/20 0.42
LTK P29376 2/20 0.42
KDR P35968 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tert-Butyl Formate SCHEMBL27910758 0.86 PIK3CA (0.43) PIK3CAPIK3R1JAK3MTORATR
SCHEMBL3339976 0.80 PIK3CA (0.51) PIK3CAPIK3R1JAK3MTORATR
SCHEMBL5413458 0.74 PIK3CA (0.50) PIK3CAPIK3R1JAK3MTORATR
SCHEMBL14910611 0.73 PRKCI (0.46) PIK3CAPIK3R1AURKAAURKB
SCHEMBL16835984 0.72 PIK3CA (0.48) PIK3CAPIK3R1JAK3MTORATR
SCHEMBL12006072 0.71 PIK3CA (1.00) PIK3CAPIK3R1JAK3MTORKDM4E
SCHEMBL3130856 0.70 PIK3CA (0.72) PIK3CAPIK3R1JAK3MTORTTBK1
SCHEMBL4378562 0.69 TTK (0.66) PIK3CAPIK3R1JAK3TTBK1TTBK2
SCHEMBL942469 0.69 PIK3CB (0.51) PIK3CAPIK3R1JAK3HTTSMN1; SMN2
SCHEMBL16035554 0.69 SMN1; SMN2 (0.54) HTTSMN1; SMN2KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2589592-B1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM CORP (JP) 2018-08-22 EP disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8772320-B2 2014-07-08 US disclosed
US-8772320-B2 2014-07-08 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed
CN-102958918-A Novel nicotinamide derivatives or salts thereof FUJIFILM CORP 2013-03-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK PIK3CA 633/4885PIK3R1 534/4885JAK3 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.